Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease | MicrobiomeTrials← Back to trialsNCT07113743
Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
ENROLLING_BY_INVITATIONPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-09-10Est. Completion: 2028-09-01
Enrollment target: 10 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Chronic Granulomatous Disease (CGD)X-Linked Chronic Granulomatous Disease
Background:
Chronic granulomatous disease (CGD) is a rare immune disorder caused by a mutation in the CYBB gene. People…
Bethesda, United StatesEst. completion Dec 31, 2032
Chronic Granulomatous Disease
This study is a longitudinal and cross-sectional evaluation of patients with Chronic Granulomatous Disease (CGD) who rec…
Bethesda, United StatesCompleted Jun 2, 2022